Actionable news
All posts from Actionable news
Actionable news in OMER: Omeros Corporation,

Omeros Announces Public Offering of Common Stock

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, today announced that it has commenced a registered underwritten public offering of 3,000,000 shares of its common stock. In addition, Omeros has granted the underwriter a 30-day option to purchase up to 450,000 additional shares of its common stock.

Cantor Fitzgerald & Co. is acting as the bookrunner for the offering.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to funding research and development for its OMS721 programs and clinical trials, preclinical studies, manufacturing and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

A registration statement on Form S-3 relating to the securities was filed with the Securities Exchange Commission on August 14, 2017 and was automatically effective. The securities may be offered only by means of a prospectus, including a prospectus...